Immuno-PET for Clinical Theranostic Approaches

Abstract : Recent advances in molecular characterization of tumors have allowed identification of new molecular targets on tumor cells or biomarkers. In medical practice, the identification of these biomarkers slowly but surely becomes a prerequisite before any treatment decision, leading to the concept of personalized medicine. Immuno-positron emission tomography (PET) fits perfectly with this approach. Indeed, monoclonal antibodies (mAbs) labelled with radionuclides represent promising probes for theranostic approaches, offering a non-invasive solution to assess in vivo target expression and distribution. Immuno-PET can potentially provide useful information for patient risk stratification, diagnosis, selection of targeted therapies, evaluation of response to therapy, prediction of adverse effects or for titrating doses for radioimmunotherapy. This paper reviews some aspects and recent developments in labelling methods, biological targets, and clinical data of some novel PET radiopharmaceuticals.
Type de document :
Article dans une revue
International Journal of Molecular Sciences, MDPI, 2016, 18 (1), Epub ahead of print. 〈10.3390/ijms18010057〉
Liste complète des métadonnées

Littérature citée [78 références]  Voir  Masquer  Télécharger
Contributeur : Elizabeth Bernardo <>
Soumis le : vendredi 17 novembre 2017 - 10:08:24
Dernière modification le : jeudi 20 septembre 2018 - 17:02:01
Document(s) archivé(s) le : dimanche 18 février 2018 - 13:30:46


Fichiers produits par l'(les) auteur(s)




Clément Bailly, Pierre-François Cléry, Alain Faivre-Chauvet, Mickael Bourgeois, François Guérard, et al.. Immuno-PET for Clinical Theranostic Approaches. International Journal of Molecular Sciences, MDPI, 2016, 18 (1), Epub ahead of print. 〈10.3390/ijms18010057〉. 〈inserm-01636873〉



Consultations de la notice


Téléchargements de fichiers